All In Biotech

Drug Trial Radar · NCT03392376

Agents Intervening Against Delirium in Intensive Care Unit

Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU) A Randomized, Blinded, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jun 13, 2018

Primary completion

Jul 9, 2022

Study completion Jul 2023

Sponsor

Lead sponsor
Zealand University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Centre for Research in Intensive Care (CRIC); Copenhagen Trial Unit, Center for Clinical Intervention Research; Scandinavian Critical Care Trials Group; The Danish Centre of Applied Social Science (VIVE)
First posted
Jan 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Delirium is a frequent condition in the Intensive Care Unit (ICU) with no existing evidence-based treatment. The aim of the AID-ICU study is to assess the benefits and harms of haloperidol treatment for the management of ICU acquired delirium.

Conditions

  • Delirium

Interventions

  • Haloperidol InjectionDrug

    ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.

  • Saline (0,9%)Other

    ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Days alive out of the hospital within 90 days post-randomizationTime frame: 90 days
  2. 90-day mortalityTime frame: 90 days
  3. Hospital Length of StayTime frame: 90 days

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Dept. Intensive Care, Aabenraa Hospital

    Aabenraa, Denmark

  • Dept. of Intensive Care, Aalborg University Hospital

    Aalborg, Denmark

  • Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet

    Copenhagen, Denmark

  • Dept. of Intensive Care, Herlev Hospital

    Herlev, Denmark

  • Dept. of Intensive Care, Herning Hospital

    Herning, Denmark

  • Dept. of Intensive Care, Nordsjaelland Hospital

    Hillerød, Denmark

  • Regionshospitalet Nordjylland, Hjørring

    Hjørring, Denmark

  • Dept. of Intensive Care, Holstebro Hospital

    Holstebro, Denmark

  • Dept. of Intensive Care, Zealand University Hospital, Køge

    Køge, Denmark

  • Dept. of Intensive Care, Nykøbing Falster Hospital

    Nykøbing Falster, Denmark

  • Dept of intensive care, Odense University Hospital

    Odense, Denmark

  • Dept. of Intensive Care, Zealand University Hospital Roskilde

    Roskilde, Denmark

  • Dept. of Intensive Care, Sønderborg Hospital

    Sønderborg, Denmark

  • Dept. of Intensive Care, Helsinki University Central Hospital

    Helsinki, Finland

  • Dept. of Neurosurgical Intensive Care, San Gerardo Hospital, Monza.

    Monza, Italy

  • UHW Adult Critical Care Cardiff

    Cardiff, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.